Dreyling, A. 2009. Bendamustine is a hybrid antimetabolite and alkylating agent offering new therapeutic options for the treatment of non-Hodgkin lymphomas. Hematology Meeting Reports (formerly Haematologica Reports). 2, 5 (Jun. 2009). DOI:https://doi.org/10.4081/hmr.v2i5.749.